In Brief This Week: Illumina; FDA, Exact Sciences, Epigenomics; Source BioScience; Bureau Veritas, Maxxam Analytics International; 1st Detect, Rigaku | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina said this week that its board has authorized the repurchase of up to $250 million of the company's common stock. The new repurchase program is in addition to Illumina's current program, which has $117.5 million available for share repurchases.


The US Food and Drug Administration confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review Exact Sciences' premarket approval application for the Cologuard colorectal screening test on March 27.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.